International Edition
Latest News
Technology

DasaHIT Trial: Weekend Dasatinib Noninferior in First-Line CML; Effusions Lower in Exploratory Analysis

Among 260 participants evaluated in the German Chronic Myeloid Leukemia Alliance randomized trial, known as DasaHIT, 206 patients achieved major molecular response at 24 months. Continuous dosing yielded an 81 percent response rate, while the intermittent schedule reached…

DasaHIT Trial: Weekend Dasatinib Noninferior in First-Line CML; Effusions Lower in Exploratory Analysis

Among 260 participants evaluated in the German Chronic Myeloid Leukemia Alliance randomized trial, known as DasaHIT, 206 patients achieved major molecular response at 24 months. Continuous dosing yielded an 81 percent response rate, while the intermittent schedule reached 78 percent.

Although continuous treatment favored the outcome by 3 percentage points, the intermittent dosing met the prespecified noninferiority criterion with a 15 percent margin. For patients receiving second-line or later treatment, molecular response rates reached 87 percent for continuous dosing and 62.5 percent for intermittent dosing, failing to establish noninferiority.

Investigators emphasized that subgroup analyses for later-line therapy were exploratory rather than prespecified. Grade 2 to 4 adverse events affected 58 percent of the continuous group and 56 percent of the intermittent group.

An exploratory post hoc analysis revealed differences in pleural and pericardial effusions associated with the tyrosine kinase inhibitor. These toxicities emerged in 16 percent of continuous dosing patients compared with 8 percent of those on the weekend break schedule.

Health-related quality of life outcomes also favored the intermittent schedule, with improvements appearing mainly in first-line patients while later-line participants experienced symptom deterioration. Median cumulative toxicity scores stood at 2 for both treatment arms.

Treatment Arm 24-Month MMR Rate Grade 2-4 Adverse Events Effusion Incidence
Continuous Dosing 81% 58% 16%
Intermittent Dosing 78% 56% 8%

At a median follow-up of 43 months, no study participants progressed to accelerated or blast phase chronic myeloid leukemia, and no disease-related deaths occurred. Overall survival reached 98 percent at 2 years and 97 percent at 5 years, with no statistically significant variance between the two schedules.

Trial investigators said that distinguishing tyrosine kinase inhibitor intolerance from disease resistance remains critical when modifying treatment regimens. That distinction helps clinicians determine whether to adjust doses rather than switch therapies entirely.

“Noninferior molecular efficacy with favorable effects on HRQOL and selected toxicities,” said LaRosée et al. Peter La Rosée and co-investigators regarding the intermittent schedule.

About the author: Technology Desk

Technology Desk at Archynewsy.